Dynamic Changes of Circulating Tumor DNA in Late Stage NSCLC Patients
Overview
A multi-centre observational, non-interventional study is to dynamically monitor the changes of circulating tumor DNA (ctDNA) in late stage NSCLC patients under Gefitinib treatment.
Full Title of Study: “A Multi-centre Observational Study on Dynamic Changes of Circulating Tumor DNA in Late Stage NSCLC Patients Under Gefitinib Treatment”
Study Type
- Study Type: Observational
- Study Design
- Time Perspective: Prospective
- Study Primary Completion Date: December 2017
Clinical Trial Outcome Measures
Primary Measures
- dynamic changes of circulating tumor DNA in late stage NSCLC patients under Gefitinib treatment
- Time Frame: 2 years
Participating in This Clinical Trial
Inclusion Criteria
- Provision of informed consent – Histologically confirmed stage IIIB/IV NSCLC. – Activating EGFR mutations (G719A/C/S; Exon 19 insertion/deletion; L858R; L861Q) – Able to comply with the required protocol and followed-up procedures, and able to receive oral medications Exclusion Criteria:
- Histologically confirmed small cell lung cancer or other metastatic tumors – Patient had received prior chemotherapy or EGFR-TKIs treatment – Patients who harbor Exon20 T790M mutation
Gender Eligibility: All
Minimum Age: 18 Years
Maximum Age: N/A
Are Healthy Volunteers Accepted: No
Investigator Details
- Lead Sponsor
- Wenzhou Medical University
- Provider of Information About this Clinical Study
- Principal Investigator: Chunming Ding, Professor – Wenzhou Medical University
- Overall Official(s)
- Wenfeng Li, Ph.D, Study Chair, First Affiliated Hospital of Wenzhou Medical University
- Overall Contact(s)
- Chunming Ding, Ph.D, 86-755-86690871, cmdingchina@qq.com
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.